

HR 8190

Biosimilar Insulin Access Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 8, 2020

Current Status: Sponsor introductory remarks on measure. (CR H4487)

Latest Action: Sponsor introductory remarks on measure. (CR H4487) (Sep 16, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/8190>

Sponsor

Name: Rep. Grothman, Glenn [R-WI-6]

Party: Republican • **State:** WI • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Nov 17, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 8, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 8, 2020)

Biosimilar Insulin Access Act of 2020

This bill establishes that, if the Food and Drug Administration (FDA) finds that an insulin is biosimilar to a reference product, the insulin shall be deemed interchangeable with the reference product. (A biological product is biosimilar to a reference product if the two products are highly similar and have no clinically meaningful differences; the reference product generally receives FDA approval first, but the biosimilar product is typically less expensive.)

Under current law, a biological product that is biosimilar to a reference product may be deemed interchangeable with the reference product only if it meets additional requirements. Current law provides that interchangeable products may be substituted for each other without the prescriber's involvement.

Actions Timeline

- **Sep 16, 2020:** Sponsor introductory remarks on measure. (CR H4487)
- **Sep 8, 2020:** Introduced in House
- **Sep 8, 2020:** Referred to the House Committee on Energy and Commerce.